Published in J Clin Oncol on May 02, 2005
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist (2012) 1.96
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
Treatment in advanced colorectal cancer: what, when and how? Br J Cancer (2009) 1.40
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr Oncol (2006) 1.34
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer (2011) 1.32
Interstitial permanent implantation of 125I seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Colorectal Dis (2008) 1.26
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs (2008) 1.21
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One (2013) 1.20
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol (2010) 1.17
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer (2009) 1.16
More is less -- combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol (2009) 1.15
Retroperitoneal abscess complicated with necrotizing fasciitis of the thigh in a patient with sigmoid colon cancer. World J Surg Oncol (2009) 1.15
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer (2007) 1.08
Metastatic colorectal cancer-past, progress and future. World J Gastroenterol (2007) 1.04
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res (2010) 1.00
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist (2014) 0.97
The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol (2009) 0.97
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One (2012) 0.96
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist (2010) 0.96
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol (2011) 0.95
Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther (2014) 0.95
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist (2011) 0.95
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Immunotherapy for gastrointestinal malignancies. Cancer Control (2013) 0.90
Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal (2014) 0.90
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med (2008) 0.90
First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol (2015) 0.90
Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol (2013) 0.90
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer (2010) 0.90
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther (2012) 0.89
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst (2013) 0.89
The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm (2013) 0.88
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract (2012) 0.87
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol (2012) 0.86
Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res (2014) 0.86
Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer (2006) 0.86
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol (2010) 0.86
Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer (2012) 0.85
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs (2010) 0.85
Surveillance of patients following surgery with curative intent for colorectal cancer. World J Gastroenterol (2007) 0.85
Microbubble-enhanced ultrasound exposure improves gene transfer in vascular endothelial cells. World J Gastroenterol (2006) 0.85
Outcome and safety of self-expandable metallic stents for malignant colon obstruction: a Korean multicenter randomized prospective study. Surg Endosc (2012) 0.85
Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis (2011) 0.84
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer (2011) 0.84
From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res (2010) 0.84
Advances in the treatment of metastatic colorectal cancer. Am J Ther (2009) 0.84
Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer (2013) 0.84
New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther (2010) 0.83
Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. World J Gastroenterol (2014) 0.83
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol (2014) 0.83
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer (2014) 0.83
Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective. Ther Adv Med Oncol (2011) 0.82
Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer (2012) 0.81
Role of phytochemicals in colorectal cancer prevention. World J Gastroenterol (2015) 0.81
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther (2013) 0.81
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Manag Res (2015) 0.81
Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics (2008) 0.80
Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal (2009) 0.80
Early start of chemotherapy after resection of brain metastasis from colon cancer with synchronous multiple liver metastases. Case Rep Oncol (2012) 0.80
Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol (2014) 0.80
Recent advances in the management of carcinoma of the rectum. Clin Exp Gastroenterol (2009) 0.80
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int (2016) 0.79
Antiangiogenic therapy in human gastrointestinal malignancies. Gut (2006) 0.79
Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Bioengineered (2013) 0.79
Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Arch Drug Inf (2008) 0.79
Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells. Proteome Sci (2014) 0.79
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D (2011) 0.79
Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol (2015) 0.79
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease? World J Surg (2014) 0.78
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco Targets Ther (2009) 0.78
The current state of targeted agents in rectal cancer. Int J Surg Oncol (2012) 0.78
Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology (2016) 0.78
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Invest New Drugs (2013) 0.78
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer (2015) 0.77
The challenge of metastatic colorectal cancer. Clin Med Insights Oncol (2010) 0.77
Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test. Exp Ther Med (2010) 0.77
Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther (2013) 0.77
Phase I study of 5-fluorouracil, leucovorin and bevacizumab in combination with radiation therapy in patients with locally advanced rectal cancer. Mol Clin Oncol (2013) 0.77
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol (2009) 0.77
Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol (2009) 0.77
Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. Oncotarget (2016) 0.77
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes (2014) 0.76
Targeted therapy in melanoma. Biologics (2009) 0.76
A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther (2014) 0.76
The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. Oncotarget (2016) 0.76
Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol (2009) 0.76
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics (2009) 0.76
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv Med Oncol (2015) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. Br J Radiol (2011) 0.75
Potential benefits of integration of therapies with chemoradiation in rectal cancer. Gastrointest Cancer Res (2007) 0.75
Bevacizumab plus fluorouracil: the value of being part of a developing story. J Clin Oncol (2005) 0.75
Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer. Adv Biomed Res (2016) 0.75
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Total knee arthroplasty in hemophilic arthropathy. J Bone Joint Surg Am (2002) 2.21
Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med (2007) 2.19
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 2.16
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood (2003) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat (2005) 1.52
Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw (2015) 1.51
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol (2008) 1.48
Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med (2004) 1.44
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother (2005) 1.29
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res (2010) 1.23
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol (2004) 1.22
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg (2007) 1.19
An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB (2009) 1.18
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 1.18
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res (2004) 1.16
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist (2008) 1.11
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.10
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol (2003) 1.07
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist (2011) 1.05
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med (2002) 1.05
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood (2008) 1.03
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol (2002) 1.02
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med (2013) 1.02
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol (2012) 1.00
Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist (2004) 0.97
Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther (2013) 0.96
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest (2003) 0.95
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2011) 0.95
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2010) 0.93
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol (2010) 0.93
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.93
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol (2007) 0.92
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res (2010) 0.91
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs (2012) 0.91
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer (2015) 0.90
A clinical model of dermal wound angiogenesis. Wound Repair Regen (2003) 0.88
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res (2003) 0.88
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys (2007) 0.87
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.86
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer (2002) 0.86
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer (2011) 0.84
Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg (2004) 0.84
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs (2013) 0.84
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.84
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med (2014) 0.83
Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol (2005) 0.83
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med (2013) 0.82
Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nat Rev Clin Oncol (2012) 0.82
Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin (2004) 0.82
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs (2014) 0.82
Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep (2014) 0.82
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol (2005) 0.81
Couples therapy at end of life. Psychooncology (2003) 0.81
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res (2010) 0.80
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.80
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer (2013) 0.80
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion (2005) 0.80
Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging (2015) 0.79
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf (2014) 0.79
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer (2008) 0.79
Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. Cancer J (2015) 0.78
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.78
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. Oncologist (2012) 0.78